160 related articles for article (PubMed ID: 26951945)
1. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
[TBL] [Abstract][Full Text] [Related]
2. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
3. Contemporary role of androgen deprivation therapy for prostate cancer.
Pagliarulo V; Bracarda S; Eisenberger MA; Mottet N; Schröder FH; Sternberg CN; Studer UE
Eur Urol; 2012 Jan; 61(1):11-25. PubMed ID: 21871711
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer's Perspective.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Manag Care Spec Pharm; 2019 Feb; 25(2):225-234. PubMed ID: 30698095
[TBL] [Abstract][Full Text] [Related]
5. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
6. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Demographic Factors Associated With Receipt of Non Guideline-concordant Initial Therapy for Nonmetastatic Prostate Cancer.
Hamilton AS; Fleming ST; Wang D; Goodman M; Wu XC; Owen JB; Lo M; Ho A; Anderson RT; Thompson T
Am J Clin Oncol; 2016 Feb; 39(1):55-63. PubMed ID: 24390274
[TBL] [Abstract][Full Text] [Related]
8. Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features.
Kalbasi A; Swisher-McClure S; Mitra N; Sunderland R; Smaldone MC; Uzzo RG; Bekelman JE
Cancer; 2014 Oct; 120(19):3089-96. PubMed ID: 24917426
[TBL] [Abstract][Full Text] [Related]
9. Long-term Overall Survival after External Beam Radiotherapy for Localised Prostate Cancer.
Jahreiβ MC; Incrocci L; Dirkx M; de Vries KC; Aben KKH; Bangma C; Heemsbergen WD
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e689-e698. PubMed ID: 37852813
[TBL] [Abstract][Full Text] [Related]
10. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
11. Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.
Amini A; Kavanagh BD; Rusthoven CG
Ann Transl Med; 2016 Jan; 4(1):14. PubMed ID: 26855950
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation alone versus combined with pelvic radiation for adverse events and quality of life in clinically node-positive prostate cancer.
Lee TH; Pyo H; Yoo GS; Kim JH; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Park W
Sci Rep; 2024 Apr; 14(1):8207. PubMed ID: 38589463
[TBL] [Abstract][Full Text] [Related]
13. Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer.
Tward JD; Lenz L; Gutin A; Clegg W; Kasten CR; Finch R; Cohen T; Michalski J; Kishan AU
JCO Precis Oncol; 2024 May; 8():e2300722. PubMed ID: 38748970
[TBL] [Abstract][Full Text] [Related]
14. Adherence to stage-specific treatment guidelines for patients with colon cancer.
Chagpar R; Xing Y; Chiang YJ; Feig BW; Chang GJ; You YN; Cormier JN
J Clin Oncol; 2012 Mar; 30(9):972-9. PubMed ID: 22355049
[TBL] [Abstract][Full Text] [Related]
15. The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancer.
Quon JL; Yu JB; Soulos PR; Gross CP
J Geriatr Oncol; 2013 Jan; 4(1):9-18. PubMed ID: 23482846
[TBL] [Abstract][Full Text] [Related]
16. Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
Frendl DM; FitzGerald G; Epstein MM; Allison JJ; Sokoloff MH; Ware JE
PLoS One; 2020; 15(12):e0240039. PubMed ID: 33284845
[TBL] [Abstract][Full Text] [Related]
17. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists.
Rajeev-Kumar G; Pitroda SP; Szmulewitz RZ; Skolarus T; Eggener SE; Liauw SL
Clin Genitourin Cancer; 2024 Apr; 22(4):102103. PubMed ID: 38781786
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China: A nationwide, multi-center, population-based cross-sectional study.
Zhang W; Liu H; Liu M; Ying S; Yuan R; Zeng H; Zhang Z; Han S; Si Z; Hu B; Wen S; Xu P; Yu W; Chen H; Wang L; Lin Z; Dai T; Lin Y; Xu T
Chin Med J (Engl); 2024 Apr; ():. PubMed ID: 38613214
[TBL] [Abstract][Full Text] [Related]
19. SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study.
Samper Ots PM; Muñoz García JL; Ríos Kavadoy Y; Couselo Paniagua ML; Villafranca Iturre E; Rodríguez Liñán M; Pérez Casas AM; Soria RM; Martínez BL; Torrecilla JL; Giner MC; Laborda AZ; García-Salazar MM
Rep Pract Oncol Radiother; 2015; 20(5):370-6. PubMed ID: 26549995
[TBL] [Abstract][Full Text] [Related]
20. Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.
Lebret T; Ruffion A; Latorzeff I; Zerbib M; Moreau JL; Rossi D; Pello-Leprince-Ringuet N; Perrot V; Hennequin C
Ther Adv Urol; 2018 Dec; 10(12):365-376. PubMed ID: 30574196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
